VacZine Analytics  
MarketVIEW: Parkinson's disease

Published February 2015

Parkinson's disease is a degenerative disorder of the central nervous system where main symptoms are tremor at rest, stiffness, slowing of movement and postural instability. It is estimated that 6.3 million people have Parkinson's worldwide, affecting all races and cultures. After Alzheimer's, it is the second most prevalent neurodegenerative disorder, affecting 1% of those over 60, and 4% of those over 80. Parkinson's disease is associated with a substantial economic burden estimated $14 bn in the US, 2010.

There is currently no cure for Parkinson's disease and treatments are concentrated on the management of symptoms. The concept of a therapeutic vaccine acting against alpha-synuclein has prompted biotech AFFiRiS AG to investigate a first in class vaccine (PD01A) currently in Phase I clinical testing. AFFiRiS are part of a new EU consortium SYMPATH which is also progressing another candidate PD03A also based on the technology (AFFITOPE®).

This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the current and potential market for Parkinson's disease vaccine(s) using a patient based value/volume forecast for major Western markets to 2030. The forecast gives revenues and volume shares for Western competitors in 3 uptake scenarios >40 yrs. The analysis also takes into account the possibility of prophylatic use and provides an up-to-date review on all aspects of disease epidemiology, treatment and patient management.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV049 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20% (from January 2011) Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2015 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains